Zenas BioPharma, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Waltham, MA
ZBIO chart
What traders are saying about $ZBIO
Latest postsZenas BioPharma, Inc. news
- ZBIO: SunStone and ZB021 readouts set the next development decisions
TradingView ·
- ZBIO: 4Q26 brings SunStone results and first ZB021 SAD/MAD data
TradingView ·
- Phase 3 Data Might Change The Case For Investing In Zenas BioPharma Stock (ZBIO)
Simply Wall Street ·
- Zenas BioPharma, Inc. Estimates – NASDAQ:ZBIO
TradingView ·
- Zenas BioPharma (ZBIO) Just Gave The Market Something To Think About
Simply Wall Street ·
- Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know
Yahoo Finance ·
- CABA,PFX,ELUT,HYPD,ZBIO,ALT,SELF,ENTX,SRBK,MAIA,PCF,LUCK,MDRR,GAIA,CFBK,SPMC,GEF-B,MDBH,IRIX,RAL,RNXT,AIRJ | Stock Prices | Quote Comparison - Yahoo Finance
Yahoo! Finance Canada ·
- CABA,PFX,ELUT,HYPD,ZBIO,ALT,SELF,ENTX,SRBK,MAIA,LUCK,PCF,GAIA,CFBK,MDRR,SPMC,GEF-B,MDBH,IRIX,RAL,RNXT,AIRJ | Stock Prices | Quote Comparison
Yahoo! Finance Canada ·
- Zenas BioPharma Stock Gains Attention After Long Term Trial Data
Yahoo Finance ·
- Zenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data Release
Yahoo Finance ·
- Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
Yahoo Finance ·
- Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026
Yahoo Finance ·
Zenas BioPharma, Inc. key financials
| USD | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $10.0M | $5.0M | $50.0M |
| Net income | -$377.7M | -$157.0M | -$37.1M |
| Diluted EPS | $-8.44 | $-11.89 | $-24.25 |
| Total assets (year end) | $383.6M | $370.0M | $68.2M |
| Cash and equivalents (year end) | $110.6M | $319.7M | $56.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Zenas BioPharma, Inc.
- Ticker
- ZBIO (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1953926
- Former names
- Zenas BioPharma (Cayman) Ltd
Frequently asked questions
What exchange is Zenas BioPharma, Inc. listed on?
Zenas BioPharma, Inc. trades on the Nasdaq under the ticker symbol ZBIO.
What industry is Zenas BioPharma, Inc. in?
Zenas BioPharma, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Zenas BioPharma, Inc. headquartered?
Zenas BioPharma, Inc.'s business address on file with the SEC is in Waltham, MA.
When does Zenas BioPharma, Inc.'s fiscal year end?
Zenas BioPharma, Inc.'s fiscal year ends on December 31.
How much revenue did Zenas BioPharma, Inc. report?
Zenas BioPharma, Inc. reported $10.0M in revenue for calendar year 2025, according to its SEC filings.